<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37016193</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Negative ANA-IIF in SLE patients: what is beyond?</ArticleTitle><Pagination><StartPage>1819</StartPage><EndPage>1826</EndPage><MedlinePgn>1819-1826</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-023-06577-w</ELocationID><Abstract><AbstractText Label="UNLABELLED">The antinuclear antibody (ANA) test has high sensitivity in diagnosing and classifying systemic lupus erythematosus (SLE).</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To describe the immunological pattern of SLE patients through investigating specific antinuclear autoantibodies by enzyme dot immunoassay and studying their frequency in both positive and negative ANA indirect immunofluorescence assay (IIF) cases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a cross-sectional study, blood samples from 393 newly diagnosed SLE patients were analyzed using (IIF) on HEp-2 cells and ANA dot immunoassay by automated enzyme immunoassay (EIA) to detect 19 antibodies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ninety-one percent of the patients are females; their mean age was 37&#x2009;&#xb1;&#x2009;12.28. Antinuclear antibody (ANA) was detected by IIF in 82.4% of cases, with 181 (46.1%) speckled and 167 (42.4%) homogeneous ANA patterns. The majority of patients (96%) demonstrated autoantibodies via EIA. Among the ANA-IIF-negative patients, 97.2% demonstrated autoantibodies. There was a significant difference in the frequency of certain autoantibodies between SLE patients with negative and positive ANA-IIF (1.44 0.73, 3.12 2.09, p&#x2009;=&#x2009;0.00) respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results of analyzing 19 autoantibodies with the ANA staining pattern increased the significance of analyzing the immune profile even if IIF is negative when clinical symptoms strongly suggest SLE diagnosis. Certain autoantibodies may evade staining by the IFA approach while they are present in the patient's serum, and they may not be detected by the ANA EIA profile if it does not contain that antigenic substrate. Key Points &#x2022; Indirect immunofluorescence on Hep-2 is the conventional method for ANA detection and is regarded as the "gold standard" for testing in clinical practice for SLE. &#x2022; In our study, ANA profile dot enzyme immunoassay (EIA)-based test was performed to evaluate 19 autoantibodies in SLE patients either positive or negative for ANA-IIF. &#x2022; The presence of anti-dsDNA with ANA-IIF-negative serum in 32.4% of SLE patients provides evidence that not all anti-dsDNA antibodies are identified on standard HEp-2 substrates. &#x2022; certain autoantibodies can evade staining by the ANA-IIF method despite being present in the SLE patient's blood; this supports the ANA profile enzyme dot immunoassay as a more sensitive test.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abozaid</LastName><ForeName>Hanan Sayed M</ForeName><Initials>HSM</Initials><Identifier Source="ORCID">0000-0003-1601-2578</Identifier><AffiliationInfo><Affiliation>Rheumatology &amp; Rehabilitation Department, Sohag Faculty of Medicine, Sohag University Hospital, Sohag, 82524, Egypt. hanan72eg@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hefny</LastName><ForeName>Hesham M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Clinical Pathology Department, Sohag University Hospital, Sohag, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abualfadl</LastName><ForeName>Esam M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Rheumatology &amp; Rehabilitation Department, Sohag Faculty of Medicine, Sohag University Hospital, Sohag, 82524, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>Mohamad A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Rheumatology &amp; Rehabilitation Department, Sohag Faculty of Medicine, Sohag University Hospital, Sohag, 82524, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noreldin</LastName><ForeName>Amal K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, Sohag University Hospital, Sohag, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eldin</LastName><ForeName>Ahmed N Nour</ForeName><Initials>ANN</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, Sohag University Hospital, Sohag, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goda</LastName><ForeName>Asmaa M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Medical Microbiology and Immunology, Faculty of Medicine, Sohag University, Sohag, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Amal H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Medical Microbiology and Immunology, Faculty of Medicine, Aswan University, Aswan, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="Y">Antibodies, Antinuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019084" MajorTopicYN="N">Fluorescent Antibody Technique, Indirect</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ANA EIA</Keyword><Keyword MajorTopicYN="N">ANA-IIF</Keyword><Keyword MajorTopicYN="N">SLE</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>4</Day><Hour>23</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37016193</ArticleId><ArticleId IdType="pmc">PMC10267001</ArticleId><ArticleId IdType="doi">10.1007/s10067-023-06577-w</ArticleId><ArticleId IdType="pii">10.1007/s10067-023-06577-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hern&#xe1;ndez Ram&#xed;rez DF, Cabiedes J. Immunological techniques that support the diagnosis of the autoimmune diseases. Reumatol Clin (Engl Ed) 2010;6(3):173&#x2013;177. doi: 10.1016/j.reuma.2009.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reuma.2009.10.003</ArticleId><ArticleId IdType="pubmed">21794705</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahler M, Meroni PL, Bossuyt X, Fritzler MJ (2014) Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res&#xa0;2014:315179. 10.1155/2014/315179</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4020446</ArticleId><ArticleId IdType="pubmed">24868563</ArticleId></ArticleIdList></Reference><Reference><Citation>Irure-Ventura J, L&#xf3;pez-Hoyos M. Disease criteria of systemic lupus erythematosus (SLE); the potential role of non-criteria autoantibodies. J Transl Autoimmun. 2022;5:100143. doi: 10.1016/j.jtauto.2022.100143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2022.100143</ArticleId><ArticleId IdType="pmc">PMC8761754</ArticleId><ArticleId IdType="pubmed">35072035</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi MY, Clarke AE, St. Pierre Y, Hanly JG, Urowitz MB, Romero&#x2010;Diaz J, ... Fritzler MJ (2019) Antinuclear antibody&#x2013;negative systemic lupus erythematosus in an international inception cohort. Arthritis Care Res 71(7):893-902</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7268889</ArticleId><ArticleId IdType="pubmed">30044551</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi MY, FitzPatrick RD, Buhler K, Mahler M, Fritzler MJ. A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus. Autoimmun Rev. 2020;19(3):102463. doi: 10.1016/j.autrev.2020.102463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102463</ArticleId><ArticleId IdType="pubmed">31927088</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossuyt X, De Langhe E, Borghi MO, Meroni PL. Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases. Nat Rev Rheumatol. 2020;16(12):715&#x2013;726. doi: 10.1038/s41584-020-00522-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-00522-w</ArticleId><ArticleId IdType="pubmed">33154583</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwer R, Vree Egberts WT, Hengstman GJ, Raijmakers R, van Engelen BG, Peter Seelig H, ... van Venrooij WJ (2001) Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Res Ther 4:1&#x2013;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC83843</ArticleId><ArticleId IdType="pubmed">11879549</ArticleId></ArticleIdList></Reference><Reference><Citation>Almagro RM, Roger AJ, Guti&#xe9;rrez FJR, D&#xed;az RS, Cardiel MH, Maestrojuan JJS. Association of anti-Ro52, anti-Ro60 and anti-La antibodies with diagnostic, clinical and laboratory features in a referral hospital in Jerez. Spain Reumatol Clin (Engl Ed) 2016;12(5):256&#x2013;262. doi: 10.1016/j.reuma.2015.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reuma.2015.10.010</ArticleId><ArticleId IdType="pubmed">26725021</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradhan VD, Badakere SS, Bichile LS, Dolas MP. Antibodies to Ro/SS-A and La/SS-B in systemic lupus erythematosus and other autoimmune disorders. J Assoc Physicians India. 2002;50:762&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">12240838</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526&#x2013;1533. doi: 10.1056/NEJMoa021933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa021933</ArticleId><ArticleId IdType="pubmed">14561795</ArticleId></ArticleIdList></Reference><Reference><Citation>Dema B, Charles N. Autoantibodies in SLE: specificities, isotypes and receptors. Antibodies. 2016;5(1):2. doi: 10.3390/antib5010002.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib5010002</ArticleId><ArticleId IdType="pmc">PMC6698872</ArticleId><ArticleId IdType="pubmed">31557984</ArticleId></ArticleIdList></Reference><Reference><Citation>Anis S, Fatima A, Abdul Jabbar S, Arain T (2022) ANA-specific antibodies, ANA patterns, anti-ds-DNA results, and clinical diagnosis: a laboratory and clinical audit. Immunol Res 1&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">36456720</ArticleId></ArticleIdList></Reference><Reference><Citation>Gualtierotti R, Meroni PL, Beltagy A, El-Girby A, Emmi G, Chizzolini C, ... Moroni G (2022) Are IF-ANA the guiding light for SLE classification in the real-world setting? Autoimmun Rev 103138</Citation><ArticleIdList><ArticleId IdType="pubmed">35809881</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarazi M, Gaffney RG, Kushner CJ, Chakka S, Werth VP. Cutaneous lupus erythematosus patients with a negative antinuclear antibody meeting the American College of Rheumatology and/or Systemic Lupus International Collaborating Clinics criteria for systemic lupus erythematosus. Arthritis Care Res. 2019;71(11):1404&#x2013;1409. doi: 10.1002/acr.23916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23916</ArticleId><ArticleId IdType="pubmed">31058462</ArticleId></ArticleIdList></Reference><Reference><Citation>Velammal Petchiappan AG, Selvam S, Nagaprabu V. ANA immunofluorescence versus profile-how well they perform in autoimmune diseases: an analysis of their clinical utility in a tertiary care centre. Int J Res Med Sci. 2018;6:3140. doi: 10.18203/2320-6012.ijrms20183659.</Citation><ArticleIdList><ArticleId IdType="doi">10.18203/2320-6012.ijrms20183659</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisetsky DS, Spencer DM, Rovin B, Lipsky PE. Role of ANA testing in the classification of patients with systemic lupus erythematosus. Ann Rheum Dis. 2021;80(8):e124&#x2013;e124. doi: 10.1136/annrheumdis-2019-216259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-216259</ArticleId><ArticleId IdType="pubmed">31540932</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarc&#xf3;n GS, Gordon C, Merrill JT, Fortin PR, Magder LS. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677&#x2013;2686. doi: 10.1002/art.34473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastin M, Mahmoudi M, Sahebari M, Tabasi N. Clinical &amp; immunological characteristics in systemic lupus erythematosus patients. Indian J Med Res. 2017;146(2):224. doi: 10.4103/ijmr.IJMR_1356_15.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijmr.IJMR_1356_15</ArticleId><ArticleId IdType="pmc">PMC5761032</ArticleId><ArticleId IdType="pubmed">29265023</ArticleId></ArticleIdList></Reference><Reference><Citation>Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, ... Shoenfeld Y (2014) International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 73(1):17&#x2013;23</Citation><ArticleIdList><ArticleId IdType="pubmed">24126457</ArticleId></ArticleIdList></Reference><Reference><Citation>Dellavance A, Gabriel J&#xfa;nior A, Cintra AF, Ximenes AC, Nuccitelli B, Taliberti BH, ... Santos WSD (2003) II Consenso Brasileiro de Fator Antinuclear em C&#xe9;lulas HEp-2: definitions for standardization of autoantibody testing against the nucleus (ANA HEp-2), nucleolus, cytoplasm and mitotic apparatus, as wel as its clinical associations. Rev Bras Reumatol Engl Ed 43:129&#x2013;140</Citation></Reference><Reference><Citation>Solomon DH, Kavanaugh AJ, Schur PH, American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Care Res. 2002;47(4):434&#x2013;444. doi: 10.1002/art.10561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10561</ArticleId><ArticleId IdType="pubmed">12209492</ArticleId></ArticleIdList></Reference><Reference><Citation>Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis. 2010;69(8):1420&#x2013;1422. doi: 10.1136/ard.2009.127100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2009.127100</ArticleId><ArticleId IdType="pubmed">20511607</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux J, Andrade LE, Fritzler MJ, Shoenfeld Y. Autoantibodies 2015: from diagnostic biomarkers toward prediction, prognosis and prevention. Autoimmun Rev. 2015;14(6):555&#x2013;563. doi: 10.1016/j.autrev.2015.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2015.01.017</ArticleId><ArticleId IdType="pubmed">25661979</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebastian W, Roy A, Kini U, Mullick S. Correlation of antinuclear antibody immunofluorescence patterns with immune profile using line immunoassay in the Indian scenario. Indian J Pathol Microbiol. 2010;53(3):427.</Citation><ArticleIdList><ArticleId IdType="pubmed">20699497</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman S, Adhya AK, Pradhan PK, Dash K, Senapati U. Correlation of indirect immunofluorescence &amp; line immunoassay method in detection of autoimmune diseases: an observational study at a tertiary care teaching hospital. Sch J App Med Sci. 2017;5(7A):2520&#x2013;2526.</Citation></Reference><Reference><Citation>Al Dowaiki S, Siddiqi AA, Al Kaabi J, Siddiqui UA, Khan MAU. Demographic, clinical and immunological manifestations of systemic lupus erythematosus among Omani population single tertiary care experience. J Liaquat Univ Med Health Sci. 2018;17(04):208&#x2013;214. doi: 10.22442/jlumhs.181740579.</Citation><ArticleIdList><ArticleId IdType="doi">10.22442/jlumhs.181740579</ArticleId></ArticleIdList></Reference><Reference><Citation>Vila LM, Mayor AM, Valentin AH, Garcia-Soberal M, Vila S. Clinical and immunological manifestations in 134 Puerto Rican patients with systemic lupus erythematosus. Lupus. 1999;8(4):279&#x2013;286. doi: 10.1191/096120399678847803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120399678847803</ArticleId><ArticleId IdType="pubmed">10413206</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosca M, Costenbader KH, Johnson SR, Lorenzoni V, Sebastiani GD, Hoyer BF, ... Touma Z (2019) How do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development of new classification criteria. Arthritis Rheum 71(1):91&#x2013;98</Citation><ArticleIdList><ArticleId IdType="pubmed">30035365</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Hishmeh M, Sattar A, Zarlasht Z, Ramadan M, Abdel-Rahman AJ, Hinson SA, Shabarek N. Rare case of lupus nephritis with negative antinuclear antibodies, double-stranded DNA antibodies and positive anti-Ro/SSA antibodies. World J Nephrol Urol. 2016;5(2):48&#x2013;49. doi: 10.14740/wjnu272e.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/wjnu272e</ArticleId></ArticleIdList></Reference><Reference><Citation>Almagro RM, Roger AJ, Guti&#xe9;rrez FJR, D&#xed;az RS, Cardiel MH, Maestrojuan JJS. Association of anti-Ro52, anti-Ro60 and anti-La antibodies with diagnostic, clinical and laboratory features in a referral hospital in Jerez. Spain Reumatol Clin. 2016;12(5):256&#x2013;262. doi: 10.1016/j.reuma.2015.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reuma.2015.10.010</ArticleId><ArticleId IdType="pubmed">26725021</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwer R, Vree Egberts WT, Hengstman GJ, Raijmakers R, van Engelen BG, Peter Seelig H, ... van Venrooij WJ (2001) Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Res Ther 4:1&#x2013;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC83843</ArticleId><ArticleId IdType="pubmed">11879549</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>